(P09-032-25) Optimizing Sleep and Mood Regulation Through Nutritional Interventions: Insights From Nutrify Genie-AI

Objectives: Sleep disorders and mood imbalances are common, with conventional treatments often causing adverse effects. Safer, long-term alternatives are needed. This study explores the potential of nutrition in managing sleep and mood disorders and evaluates Nutrify Genie AI (NG-AI) for identifying natural compounds that modulate these processes without side effects.

1. Explore nutrition’s role in regulating sleep and mood.
2. Assess NG-AI’s ability to map nutritional pathways.
3, Validate predictions through molecular docking of natural compounds.
4. Provide personalized nutritional recommendations using NG-AI.

Methods: NG-AI, a novel discovery platform was used to identify natural compounds targeting key receptors/biomarkers, including Orexin receptor, MT1, and TNF-α for sleep and mood. The target key receptors highlights the role in sleep wake cycle, mood and inflammation. Complex molecular docking analysis determined their binding affinities for progressing interventions.

Results: 8beta-(4’hydroxytigloyloxy)costunolide showed strong binding to OX1R (-8.41 kcal/mol) and MT1 (-8.51 kcal/mol), indicating potential for sleep and mood regulation. It also bound to IL-1β (-6.33 kcal/mol). Neferine targeted TNF-α (-6.28 kcal/mol), suggesting anti-inflammatory effects for sleep and mood. Suvorexant, a synthetic drug, had similar binding affinities (-8.016 kcal/mol) to OX1R, highlighting the potential of natural alternatives with fewer side effects. Orexin receptor activation influences neurotransmitters (e.g., norepinephrine, serotonin) delaying sleep onset. These findings suggest 8beta-(4’hydroxytigloyloxy)costunolide and Neferine as safer alternatives to Suvorexant for sleep regulation.

Conclusions: Study highlights NG-AI potential in discovering natural compounds for sleep and mood regulation. 8beta-(4’hydroxytigloyloxy)costunolide and Neferine emerge as promising, safer alternatives to synthetic drug for sleep and mood disorders.

Funding Sources: No external funding sources or financial support.